Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | PVSRIPO |
| Trade Name | |
| Synonyms | PVS-RIPO|NSC-719277|NSC719277 |
| Drug Descriptions |
PVSRIPO is an oncolytic virus comprising a recombinant poliovirus/rhinovirus chimera, which targets CD155 (Necl5)-expressing tumor cells, and potentially induces enhanced anti-tumor immune response and tumor cell cytotoxicity (PMID: 21984883, PMID: 24939611). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C99459 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + PVSRIPO | Atezolizumab PVSRIPO | 0 | 1 |
| Lomustine + PVSRIPO | Lomustine PVSRIPO | 0 | 1 |
| Nivolumab + PVSRIPO | Nivolumab PVSRIPO | 0 | 1 |
| Pembrolizumab + PVSRIPO | PVSRIPO Pembrolizumab | 0 | 1 |
| PVSRIPO | PVSRIPO | 0 | 5 |
| PVSRIPO + unspecified PD-1 antibody | PVSRIPO unspecified PD-1 antibody | 0 | 2 |